B

Breakthrough T1D

Nonprofit funds T1D research and advocacy

Overview

Company Does Not Provide H-1B Sponsorship

What Breakthrough T1D does: It is a global nonprofit organization that funds medical research, advocates for public policy changes, and speeds development of therapies for type 1 diabetes (T1D). How its product works: It does not sell a product; instead it raises funds through donations and events like the Breakthrough T1D Ride, then distributes grants to researchers, supports policy advocacy with governments and regulators, and partners with healthcare groups to improve access to care and therapies. How it differs from competitors: It combines global research funding with public policy advocacy and community fundraising, reinvesting donations into research and program work, with a clear emphasis on accelerating therapy development and improving patient access across multiple regions (notably the US and UK). What its goal is: To eradicate type 1 diabetes by advancing research, shaping policy, and expanding access to treatments and care.

Work here?Claim your company

About Breakthrough T1D

Simplify's Rating
Why Breakthrough T1D is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Government & Public SectorSocial ImpactBiotechnologyHealthcare

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Indianapolis, IN

Founded

1970

Get referred to Breakthrough T1D

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Walgreens starts checkout fundraising in May 2027 after a $1 million commitment.
  • Congress extended the Special Diabetes Program to December 31, 2026, raising funding to $200 million.
  • FDA approval of finerenone on September 17, 2026 validates Breakthrough T1D's kidney-disease strategy.

What critics are saying

  • The T1D Fund governance fight on May 8, 2026 exposed donor-trust fractures.
  • The Special Diabetes Program expires December 31, 2026; federal renewal failure cuts research leverage.
  • If cures stall, biotech partners and donors drift toward higher-return diabetes platforms.

What makes Breakthrough T1D unique

  • Breakthrough T1D owns the T1D Fund, linking grants, advocacy, and biotech investing.
  • Its 2026 Clinical Research Congress convenes 80 sessions across 16 countries.
  • The Walgreens Foundation partnership targets $16 million through 2029, expanding community reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Company News

PR Newswire
Nov 12th, 2026
Breakthrough T1D and Walgreens Foundation join forces to support the Type 1 Diabetes community.

Breakthrough T1D and Walgreens Foundation join forces to support the Type 1 Diabetes community. Nov 12, 2026, 10:00 ET NEW YORK and DEERFIELD, Ill., Nov. 12, 2026 /PRNewswire/ - Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, and the Walgreens Foundation today announced a new national partnership supporting Breakthrough T1D's mission and advancing the Walgreens Foundation's "Care for Every Community" platform. Together, the organizations will help ensure that the 1 in 31 families impacted by T1D in the United States are healthy today for the cures of tomorrow. Through a $1 million direct cash commitment over three years, the Walgreens Foundation will support Breakthrough T1D and the T1D community by delivering trusted resources and community support and helping accelerate research toward T1D cures. Beyond this direct commitment, the Walgreens Foundation aims to raise $15 million over three years for Breakthrough T1D through checkout fundraising campaigns in Walgreens stores, with the first campaign launching in May 2027. "Breakthrough T1D is excited to welcome the Walgreens Foundation as a national partner, and we are deeply grateful for their generous commitment to the type 1 diabetes community," said Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D. "Walgreens is already a steady and trusted local presence in communities, helping this partnership meet people where they already receive care. With a shared focus on improving lives and building a healthier tomorrow, partners like the Walgreens Foundation are essential to making everyday life with type 1 diabetes better today while we work toward cures. We look forward to the positive impact we can create together." Through this partnership, the Walgreens Foundation will support community awareness, education, and engagement programs focused on T1D, early detection, and clinical trials, and pharmacists will receive access to ACPE-accredited continuing education activities that will help strengthen care for those living with T1D. In May 2027, Walgreens stores will launch the first of these checkout campaigns, raising important funds for Breakthrough T1D and T1D research and giving customers an easy way to support the T1D community by making a voluntary donation at checkout. "Walgreens has served as a cornerstone in neighborhoods across the country for more than a century, helping people lead healthier lives through personal care, trusted advice, and accessible services," said Abbe Luersman, Walgreens Executive Vice President, Chief Human Resources Officer, and President of the Walgreens Foundation. "With more than 1.5 million Americans living with type 1 diabetes today and incidence rates rising, the Walgreens Foundation has a tremendous opportunity to support the community and help people truly see T1D through this partnership with Breakthrough T1D. Together, we strive to reach one person with T1D for every Walgreens team member, making this a true community effort with a collective impact." The contributions of national partners like the Walgreens Foundation help build critical awareness of T1D and engagement with the broader community and fund research that is advancing the development of disease-modifying therapies that can change the course of T1D, early detection, technology to help with day-to-day T1D management, treatments that address complications of T1D, and cell therapies that may one day cure the disease. About Breakthrough T1D, Formerly JDRF As the leading global type 1 diabetes research and advocacy organization, Breakthrough T1D helps make everyday life with type 1 diabetes better while driving toward cures. We do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition. About Walgreens Founded in 1901, Walgreens proudly serves nearly 9 million customers and patients each day across its approximately 8,500 stores throughout the U.S. and Puerto Rico. Walgreens has approximately 220,000 team members, including nearly 90,000 healthcare service providers, and is committed to being the first choice for pharmacy, retail, and health services, building trusted relationships that create healthier futures for customers, patients, team members, and communities. About Type 1 Diabetes (T1D) T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short and long-term complications, which can include highs and lows in blood glucose; damage to the kidneys, eyes, nerves, and heart; and even death. Globally, it impacts 9.5 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all new T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D. SOURCE Breakthrough T1D, Formerly JDRF

GlobeNewswire
Oct 6th, 2026
Breakthrough T1D strengthens cybersecurity and IT resilience with Managed IT Services from Canon and Supra ITS.

Breakthrough T1D strengthens cybersecurity and IT resilience with Managed IT Services from Canon and Supra ITS. Customer example highlights how proactive cybersecurity and cloud-based IT can help organizations protect critical operations during Cybersecurity Awareness Month. Melville, NY, Oct. 06, 2026 (GLOBE NEWSWIRE) - As organizations across the country recognize Cybersecurity Awareness Month, Breakthrough T1D, the leading global nonprofit organization dedicated to funding type 1 diabetes (T1D) research, advocacy and support programs, is highlighting the importance of maintaining a secure, resilient technology environment to support its mission worldwide. Breakthrough T1D partnered with Canon Canada and Supra ITS, Canon's Managed IT Services partner, to modernize its IT infrastructure, strengthen cybersecurity and support its distributed workforce. The organization's transformation demonstrates how a proactive approach to IT management and cybersecurity can help organizations protect critical systems and data while enabling employees to remain focused on their missions. "Technology needs to support our mission, not stand in its way," said Alan Burvill of Breakthrough T1D. "The partnership with Canon and Supra ITS has helped us keep our data secure and ensure our teams have the technology they need to continue our work." During the COVID-19 pandemic, Breakthrough T1D needed to quickly transition to remote operations while keeping critical fundraising and donation systems online. The organization's partnership with Canon and Supra ITS helped facilitate that transition while establishing a foundation for ongoing IT management and cybersecurity. Today, Breakthrough T1D continues to benefit from cloud infrastructure, proactive monitoring, cybersecurity management and ongoing IT support. The organization's experience underscores the importance of taking a proactive approach to cybersecurity as businesses and nonprofits navigate increasingly distributed workforces, cloud environments and evolving cyber threats. "Breakthrough T1D demonstrates how managed IT services can provide organizations with the security, reliability and flexibility they need without adding complexity to their operations," said Justin Folkerts, COO, Supra ITS. Canon's Managed IT Services through Supra ITS provide integrated IT support, cybersecurity and infrastructure management designed to help organizations reduce downtime, strengthen security and improve operational efficiency. With ISO 27001 and SOC 2 Type II certifications, Supra ITS provides scalable services that help organizations manage evolving technology needs without expanding internal IT resources. Building on Canon Canada's experience delivering Managed IT Services, Canon U.S.A. now offers these services through Supra ITS to organizations across the United States. About Breakthrough T1D: Breakthrough T1D, formerly known as JDRF (Juvenile Diabetes Research Foundation), is the leading global organization dedicated to type 1 diabetes (T1D) research, advocacy, and support. Founded in 1970 by families, it works to accelerate life-changing breakthroughs to cure, prevent, and treat T1D and its complications. About Supra ITS Supra ITS is a Canadian company that specializes in Information and Communications Technology solutions, and it operates as a Canon Managed IT Services Partner. Over the years, the company has built a reputation for providing high-quality, proactive, and exceptional customer service. Supra ITS has a diverse clientele that includes blue-chip multinationals, government agencies, and small to medium-sized enterprises. With an experienced team, cutting-edge tools, and unparalleled expertise, Supra ITS offers a wide spectrum of services, including Managed IT, Cyber-Security, Business Process Outsourcing, and Custom Application Development, to meet the unique needs of its clients. About Canon Canada Inc. Headquartered in Brampton, Ontario, Canon Canada Inc., a wholly owned subsidiary of Canon U.S.A. Inc., is a leading provider of consumer and business-to-business digital imaging solutions. Innovation and cutting-edge technology have been essential ingredients in Canon's success. Canon Canada Inc. is committed to the highest level of customer satisfaction and loyalty, providing 100 per cent Canadian-based service and support for all of the products it distributes. Canon Canada Inc. is dedicated to its Kyosei philosophy of social and environmental responsibility. For more information, please visit canon.ca or follow the company on Facebook, Twitter (X), LinkedIn or Instagram using @CanonCanada. About Canon U.S.A., Inc. Canon U.S.A., Inc. is a leading provider of consumer, business-to-business, and industrial digital imaging solutions to the United States, Canada, Latin America, and the Caribbean markets. With approximately $29.5 billion in global revenue, its parent company, Canon Inc., as of 2025 has ranked in the top-10 for U.S. patents granted for 42 consecutive years.[Footnote1] Canon U.S.A. is dedicated to its Kyosei philosophy of social and environmental responsibility. To learn more about Canon, visit www.usa.canon.com and connect with us on LinkedIn at www.linkedin.com/company/canonusa. * Based on patent counts issued by the United States Patent and Trademark Office and compiled by IFI CLAIMS Patent Services.

The Business Press
Oct 5th, 2026
Lindsay Pittard.

Lindsay Pittard. October 5, 2026 Breakthrough T1D North Texas Area has announced Lindsay Pittard as its new territory executive director for the Dallas, Fort Worth and Oklahoma Chapters of Breakthrough T1D. - Digital Sponsors - (C) The Business Press P.O. Box 6016, Fort Worth, TX 76115

Breakthrough T1D
Oct 5th, 2026
Breakthrough T1D to host inaugural Type 1 Diabetes Clinical & Research Congress.

Breakthrough T1D to host inaugural Type 1 Diabetes Clinical & Research Congress. October 5, 2026 Event Will Convene Global Leaders to Shape the Future of Type 1 Diabetes in Philadelphia October 9-11 PHILADELPHIA, Pa., Oct. 5, 2026 - Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is proud to announce the inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026). This landmark gathering of the global T1D community will take place from October 9-11, 2026, in Philadelphia, Pennsylvania. CRC 2026 will serve as a one-of-a-kind forum for bringing together world-renowned clinicians, researchers, scientists, healthcare professionals, industry leaders, and community advocates across two and a half days of programming. The Congress is designed to foster collaboration, spur innovation, and provide translational insights with the shared goal of improving lives and driving toward a world without T1D. "The first Breakthrough T1D Clinical & Research Congress is inspired by the belief that drives our work: people with type 1 diabetes deserve better care options today as we work toward a future without this condition," said Aaron J. Kowalski, Ph.D., Chief Executive Officer of Breakthrough T1D. "As a forum focused solely on type 1 diabetes, we're connecting the science with real-world implementation and lived experience to transform the future of T1D." Attendees will have the opportunity to explore the latest scientific and clinical advances during more than 80 scientific sessions on a wide spectrum of critical focus areas, including: * The Use of AI, Advanced Immune Profiling, Digital Twin Technologies & Other Emerging Technologies * Pushing Toward Cures: Islet Cell & Disease-Modifying Therapies * Addressing the Shortage of Endocrinologists * Discovery Science & Immunotherapies * Screening Guidelines for Early-Stage T1D * Unmet Needs of the T1D Community & Access Gaps in Diabetes Care CRC 2026 co-chairs Dr. Thomas Danne, Dr. Sanjoy Dutta, and Dr. Anastasia Albanese-O'Neill of Breakthrough T1D and the esteemed Clinical and Research Committee worked to assemble a faculty of speakers and presenters that include leaders from more than 16 countries and dozens of top global institutions. Some featured speakers include: Dr. Brynn Marks, Breakthrough T1D; Dr. Colin Dayan, University of Birmingham; Dr. Juan Alvarez-Dominguez, University of Pennsylvania; Dr. Tandy Aye, Stanford School of Medicine; Dr. Michael Haller, University of Florida; Dr. David Ahn, Mary & Dick Allen Diabetes Center; and many more. Dr. Thomas Danne, Chief Medical Officer, International, said: "The science of T1D is moving beyond managing blood sugar alone. We are learning more about how the disease develops, how to protect or replace insulin-producing cells, and how to make daily care more precise. The questions before us now are which approaches will work, for whom, and how quickly we can bring them to patients." Dr. Sanjoy Dutta, Chief Scientific Officer, said: "Some of the most important questions in T1D cannot be answered by one area of research alone. At the Breakthrough T1D Clinical & Research Congress, scientists working on the immune system, insulin-producing cells, and emerging technologies will have the chance to challenge and build on one another's findings. Those connections can help us understand the disease more fully and accelerate the paths to cures." Dr. Anastasia Albanese-O'Neill, Senior Vice President of Medical Affairs, said: "Scientific advances only make a difference when they can improve someone's care. At the Breakthrough T1D Clinical & Research Congress, we'll look beyond what is possible in the lab to the questions clinicians and people with T1D face every day: who can benefit, how care can be tailored to their needs, and what it will take to make new options accessible." CRC 2026 is poised to usher in a new moment for the T1D community as it reaches an inflection point on its path toward cures. For more information about the event, visit bt1dcongress.org About Breakthrough T1D As the leading global type 1 diabetes research and advocacy organization, Breakthrough T1D helps make everyday life with type 1 diabetes better while driving toward cures. Rock Type 1 do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition. About Type 1 Diabetes (T1D) T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short and long term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death. Globally, it impacts 9.5 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.

San Francisco Biotechnology Network
Sep 22nd, 2026
Encellin partners with Breakthrough T1D to advance immune-protected Cell Therapy for Type 1 Diabetes.

Encellin partners with Breakthrough T1D to advance immune-protected Cell Therapy for Type 1 Diabetes. SAN FRANCISCO & NEW YORK & MONTREAL-(BUSINESS WIRE)-Encellin, Inc., a clinical-stage biotechnology company developing Encapsulated Cell Replacement Therapy (ENCRT), today announced a partnership with Breakthrough T1D, the leading global Type 1 Diabetes (T1D) research and advocacy organization, and an award through its Industry Discovery and Development Partnership (IDDP) program to support the advancement of Encellin's ENCRT-103-hPI clinical program in T1D. The new trial (NCT07680673) will br Click here to view original post

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Breakthrough T1D right now.

Find jobs on Simplify and start your career today

We update Breakthrough T1D's jobs every few hours, so check again soon!Browse all jobs